<Anchor> As

the world is looking forward to developing and selling Corona 19 vaccines and treatments, clinical trials of Corona 19 vaccine began for the first time in Korea yesterday (15th).

Reporter Nam Joo-hyun has been to the scene.

<Reporter> This

is the first clinical trial participant to receive Corona 19 vaccine in Korea.

[You will be a little sick. It's stiff.] A

typical vaccine ends with an injection, but this vaccine requires one more step of applying electrical stimulation to the injection site.

[Park Wan-beom/Seoul National University Hospital Infectious Medicine Professor: Because it is a DNA vaccine, a'electroporation' process is needed to open the cell membrane. So, the injection is performed first, and then the electroporation process is continued.]

The first clinical trial for the Corona 19 vaccine in Korea is the DNA vaccine developed by Innobio of the United States.

Seoul National University Hospital plans to conduct clinical trials over a year in two stages, first, to check the safety of 40 healthy adults aged 19 to 50, and to increase the age range to 64, to check for toxicity and effectiveness.

[The first participant in the Corona 19 vaccine clinical trial: I have a child. I was able to help my child live in a corona-free world in the future, so I was able to participate.]

Beginning with a DNA vaccine from a US company, domestic clinical trials for Korean DNA vaccines in September and Korean protein recombinant vaccines will begin in September. is.

In addition, modern Americans, Oxford University, UK, and Nova Vax, USA are accelerating the development of vaccines with worldwide interest.